

Prognostic value of gated myocardial perfusion SPECT

Leslee J. Shaw, PhD,^a and Ami E. Iskandrian, MD^b

Risk assessment has become increasingly important in this era of evidence-based medicine in which new and existing technology requires a well-defined body of evidence on its societal benefit in order to support resource utilization. Historically, test accuracy has been defined by using sensitivity and specificity for the detection of obstructive coronary disease. However, this measurement is fraught with bias and poorly reflects test performance. The focus on risk assessment in cardiovascular medicine is consistent with a shift toward integrative patient management approaches whereby the extent and severity of inducible ischemia are used to guide therapeutic decision making. This change in focus allows nuclear cardiology to play a central role in patient management decisions. The estimation of prognosis with any given imaging modality allows a more precise linkage with patient risk and therapeutic risk reduction efforts. In addition, a nuclear-based focus for decision making concentrates on the physiologic significance of the disease state and its relationship to event risk.

This concept of medically guided care (including optimized anti-ischemic therapy and selective cardiac catheterization) is further promoted in our current era of cost-conscious health care. From nuclear-based strategies that provide information about patient risk, the ensuing posttest resource needs of any given patient group may also be estimated. The ensuing costs for tests that have established value in identifying prognostically significant disease states may be offset by the downstream savings in decreased morbidity and mortality. In the United States, annual expenditures for diagnosing and treating cardiovascular disease exceed \$329 billion.¹ Health care costs have risen dramatically and exceed the rate of inflation. Although rising costs reflect an increase in the prevalence of coronary heart disease and an aging population, new technology for cardiovascular disease is also a major contributor to high rates of resource utili-

zation. In the area of single photon emission computed tomography (SPECT) imaging, annualized growth rates for cardiologists have increased by more than 20%.² When one examines all of cardiovascular testing, there are an estimated 40 million noninvasive cardiac tests performed each year.³ For echocardiography and SPECT imaging, reimbursement from Medicare encompasses approximately 30% of all payments, totaling over \$1 billion in the year 2000.⁴ Thus the use of testing that importantly guides lifesaving care is a critical step toward cost-effective testing for society.

ESTIMATING RISK VERSUS DISEASE

Although the focus of the current review is the estimation of prognosis with gated myocardial perfusion SPECT, recent evidence has been synthesized to reveal that gated myocardial perfusion SPECT is a highly sensitive test for the detection of a critical stenosis.⁵ In a recent meta-analysis organized by the United Kingdom's National Institute of Clinical Excellence, diagnostic sensitivity for myocardial perfusion imaging was 87% (n = 2,971/3,425).⁵ Specificity was lower (73%; n = 772/1,055) but was influenced by the low number of patients with negative test results who underwent the gold standard, angiography.

Specificity, as a measure of test performance, is suboptimal because it fails to consider whether a flow-limiting lesion is prognostically significant, as is supported by myocardial infarction literature in which subcritical lesions often progress to the acute event.⁶ A frequently cited major limitation on the usefulness of diagnostic sensitivity and specificity is verification or workup bias. Workup bias occurs when the vast majority of patients with abnormal test results undergo the gold standard, coronary angiography, thus resulting in an overestimation in diagnostic sensitivity. Specificity is diminished (as these two measures operate as diametrically opposed calculations) because few patients with negative test results are referred to cardiac catheterization. The ensuing calculation of a high sensitivity and lower specificity, as noted in the review by Underwood et al,⁵ supports the notion of verification bias in the nuclear literature, and as such, these diagnostic measures are not useful in guiding patient referral decisions.

In addition to the problems of workup bias, there are

From the Atlanta Cardiovascular Research Institute, Atlanta, Ga,^a and the University of Alabama at Birmingham, Birmingham, Ala.^b

Reprint requests: Leslee J. Shaw, PhD, Director, Outcomes Research, 5665 Peachtree Dunwoody Rd NE, Suite 225, Atlanta Cardiovascular Research Institute, Atlanta, GA 30342; lshaw@acrionline.org. *J Nucl Cardiol* 2004;11:171-85.

Copyright © 2004 by the American Society of Nuclear Cardiology. 1071-3581/2004/\$30.00 + 0

doi:10.1016/j.nuclcard.2003.12.004

other advantages to using prognostication as a measure of test performance. The use of estimated risk versus diagnostic accuracy is advantageous in higher-risk populations including the elderly, those with peripheral arterial disease, diabetic patients, or patients with known coronary disease. It has also been shown to be helpful in populations in whom diagnosis is challenging, including the large proportion of women referred to SPECT laboratories.

SPECT RISK MARKERS SERVE AS INTERMEDIATE OUTCOME MEASURES

Thus a shift in publications from diagnostic to prognostic accuracy should be considered a tremendous advance to the field and has the benefit of coordinating outcome estimation with therapeutic randomized controlled trial data. For example, one of our greatest prognosticators in cardiovascular medicine is left ventricular ejection fraction, which is commonly estimated by gated SPECT and is inversely related to cardiac survival. Integrative management decisions can be effectively initiated based on left ventricular dysfunction measures (eg, angiotensin-converting enzyme inhibitors). In addition, these measures can provide insight into the therapeutic benefit that may result from intervention. With this example, the expected increase in life expectancy with coronary artery bypass surgery is approximately 10 years in patients with abnormal systolic function as compared with 2 years for those with normal ventricular function.^{7,8} According to this logic, measures of ventricular function and myocardial perfusion imaging may be viewed as intermediate or surrogate outcomes, in that they are indicators of future adverse sequelae. This recent paradigm has fostered further research in the area of nuclear cardiology where treatment is focused on the intermediate outcome of inducible ischemia or other high-risk SPECT markers, thereby altering the expected worsening outcome in at-risk patients.⁹⁻³¹ We await further research in this area of nuclear cardiology where treatment is wholly integrated and focused based on SPECT imaging results, such as with the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) and Adenosine Sestamibi Post-Infarction Evaluation (INSPIRE) trial results.

RISK THRESHOLDS

One of the clear benefits of using risk estimation is that it can be coordinated within population-based risk thresholds. We do know that the underlying risk in the population varies with a patient's pretest risk, such that patients without coronary disease have lower rates of coronary disease events than those with disease (ie,

approximately 1% vs 2%, on average). Population risk in those without disease may be estimated by use of one of many global risk scores (eg, Framingham risk³²). In a diagnostic population, risk is substantially lower than in a population with existing cardiovascular disease or for those disease-equivalent patients (eg, diabetic patients).³² Thus stratification of risk must initially consider the pretest risk in the population. Beginning with a diagnostic population, optimal candidates for imaging include those intermediate-risk patients. Intermediate-risk patients may be defined as those for whom the rate of cardiac death or nonfatal myocardial infarction ranges from approximately 1% to 2% per year. In general, in symptomatic cohorts, intermediate-risk patients are those with 1 or more risk factors (excluding diabetes). Women with typical angina are also considered to be at intermediate risk. Risk compounds with the clustering of risk factors and symptom burden, such that multiple risk factors increase the risk in the population and patients with more frequent and unstable symptoms are at increasing risk.

Intermediate-risk patients are then allocated to lower- or higher-risk subsets based on posttest imaging results. Low-risk candidates are those whose estimated rate of death or myocardial infarction is lower than 1% or, in patients with known coronary disease, is lower than 2%.³³ Patients with high-risk SPECT results in a diagnostic cohort are defined as those with an estimated rate of death or nonfatal myocardial infarction of approximately 2% or greater per year. Evidence supports that an even higher-risk subset of patients with (frequently severe and extensive) known coronary disease have an annual mortality rate estimation of 3% to 5% or more. All high-risk cohorts are then targeted for aggressive posttest management. Of those with suspected or known coronary disease, high-risk SPECT results are associated with a high prevalence of obstructive and/or progressive disease, and thus these patients benefit from referral to coronary angiography.

BAYESIAN THEORY

As evidenced by the prior discussion, optimal candidate selection depends on an understanding of the underlying risk in any given patient group. Extending this reasoning one additional step, appropriate patient selection for nuclear imaging will guide the added or incremental value of imaging in any pretest risk cohort. That is, by integrating risk factor, age, and symptom data into a global risk score (eg, Framingham risk score, European risk score), a patient's pretest risk may be estimated as low, intermediate, or high. Several models have been developed in large, symptomatic cohorts to predict rates of mortality as well as significant and extensive coronary disease^{8,34-36}; these prediction algo-

rhythms are based on age, sex, symptom (presence, frequency, instability), and traditional cardiac risk factors, as well as measures of systolic blood pressure and resting electrocardiographic abnormalities.

This estimation of pretest risk is the cornerstone of achieving optimal incremental value in posttest information. Thus optimal selection of candidates for SPECT is based on Bayesian theory, in which the posttest likelihood becomes a function of a patient's pretest risk. Bayesian theory may then provide us with insight as to which patient subsets will garner the greatest amount of added information from referral to nuclear imaging. In low-risk patients, the shift from pretest to posttest risk estimation is minimal. Thus this decision is ineffective and costly. A large majority of intermediate-risk patients may be shifted to lower-risk cohorts (given negative test results) or higher-risk cohorts (in the setting of moderately to severely abnormal perfusion scans). For example, published reports note that, on average, 53% of patients have normal or low-risk myocardial perfusion imaging results. Accordingly, it is expected that approximately half of intermediate-risk patients would be at low risk after testing, with an expected annual mortality rate of approximately 0.6%.³³ As one can see, a posttest shift is greatest in those patients with an intermediate pretest risk of coronary disease.

DEFINING THE EFFECTIVENESS OF CARDIAC IMAGING PRINCIPLES OF RISK STRATIFICATION

A critical step in evaluating the utility of an imaging test is its impact on patient outcome and alterations in patient management.³⁷ The evaluation of a test's ability to risk-stratify individuals has been proposed as an alternative to the challenges of assessing diagnostic accuracy.³⁸ For any given test, risk stratification may be used as a method for defining high- and low-risk cohorts where treatment is allocated to those in greatest need.⁸ Furthermore, the intensity of management is directly proportional to the estimated risk of events, such that high-cost care is allocated to high-risk patients.⁸ Of course, the economic benefit of risk stratification is that, left untreated, many of the high-risk individuals would have a cardiac event resulting in more costly care. Furthermore, identifying high-risk patients before the onset of clinical cardiovascular disease may offset the significant morbidity and mortality rates associated with more advanced disease. Conversely, low risk should equate to low cost to the health care system.

OUTCOME MEASURES

The broad range of outcome measures that are applicable to the use of risk stratification include (1) intermediate

clinical outcomes (eg, disease detected, cardiac event predicted), (2) major adverse cardiovascular events (eg, survival rates), (3) cumulative effects of test-driven strategy (eg, life years saved), (4) patient assessment of a test's value (eg, quality of life, patient preferences), and (5) combined quantity- and quality-of-life years (eg, quality-adjusted life years, healthy-year equivalent³⁷).

DEFINING THE INTERACTIVE NATURE OF RISK WITH PREDICTIVE MODELS

Risk stratification may be defined statistically as the relative risk ratio (often with 95% CIs), in which a high-risk cohort is calculated as the ratio of increased risk of events. Relative risk ratios indicate the x-fold increase in event risk in high- versus low-risk patients where a statistical increase is noted when the CIs do not include 1.0. As cardiovascular risk is often interactive, additive, or multiplicative, multivariable regression models help to define the independent contribution of any given set of variables in estimating adverse cardiac events. Thus multivariable predictive models can be used to describe the interactive nature of both historical and measured risk factors to those associated with an imaging abnormality and provide an improved method to assess the prognostic value of testing.³⁹⁻⁴⁹

A key to interpreting relative risk ratios with SPECT imaging parameters is to understand that risk increases with myocardial perfusion abnormalities (ie, directly proportional relationship) but is inversely related to measures of left ventricular function. That is, as ejection fraction measures decrease, a patient's risk increases. These opposite relationships can help to explain varying relative risk ratios where a lower risk ratio with systolic dysfunction (eg, ejection fraction = 45%) can be indicated by a relative risk ratio of 0.68, denoting a 32% increase in cardiac event risk (ie, $1 - 0.68 = 32\%$).

However, it is important to consider the difference between absolute and relative risks. In two populations of varying underlying risk (eg, suspected and chronic coronary disease), relative risk ratios may be elevated similarly; however, the overall event rate in the population may be divergent (as previously discussed).⁵⁰ An example of this could be two patients, one at intermediate risk and one with known disease, with normal perfusion findings, in whom the relative risk may be diminished but the absolute risk of death (<1% vs 1%-2% per year) is quite different. Thus critical components of risk must include an understanding of both relative and absolute risk of events.

DEFINING THE ADDED VALUE OF SPECT

The supportive rationale for the use of imaging is that symptoms, established risk factors, physical

examination, and functional status measures are often insensitive to disease states.⁵¹ SPECT's incremental value may be calculated by quantifying the amount of added information, often called the test's incremental value. In general, tests that provide more added information would be favored over those that have less prognostic content. Diagnosis costs can be high when tests add little value (ie, in low-risk individuals⁵²). As noted, SPECT imaging has a greater incremental value in intermediate-risk individuals.⁵³

CONCEPTS IN LINKING RISK ASSESSMENT TO TAILORED MEDICAL INTERVENTION

SPECT imaging provides not only information about the physiologic significance of flow-limiting disease and left ventricular function but also a global estimation of risk for major adverse cardiac events. As this is the threshold for evidence-based practice, gated SPECT is the tool optimally suited to provide information to guide patient management decisions. This concept, in terms of evidence-based medicine, is called empiric risk stratification, in which optimal improvement in outcome is achieved by linking high-risk SPECT measures to risk-reducing therapies. The optimal link is the specific event that the imaging modality identifies and the therapy applied which have also been shown to reduce outcomes. This concept of tailoring intervention based on the expected risk in the patient was initially espoused in the Bethesda Conference on secondary prevention.⁸

From gated SPECT, the optimal risk assessment tool would include markers of the amount of ischemic burden and the extent of left ventricular dysfunction. A compilation of evidence suggests that varying outcomes may be estimated when using measures of myocardial ischemia as compared with left ventricular function data. In particular, measures of the amount of myocardial ischemia have been consistently shown to predict acute ischemic events including acute myocardial infarction and worsening or unstable angina (leading to late revascularization). Measures of left ventricular function are consistently linked to end-stage cardiac events including death and heart failure. In this latter group, one would also surmise that increased lung uptake of thallium and stress-induced ventricular dilatation would also provide estimation of end-stage events in higher-risk patients (ie, with severe coronary disease).

RISK OF EVENTS IN PATIENTS WITH NORMAL OR LOW-RISK FINDINGS

By definition, principles of risk stratification would define a cohort with improved outcome (ie, low risk) and exhibit a clear separation in risk between higher-risk

subsets of the population. In the case of patients with normal perfusion findings, numerous studies over the past decade have reported uniformly low rates of major adverse cardiac outcomes. Table 1 details the current evidence in 19 published series on normal or low-risk myocardial perfusion SPECT.^{8,33,54-69} In the 19 reports, a total of 39,173 patients were reported to exhibit a median rate of major adverse cardiac events of 0.6% per annum (25th percentile = 0.5%, 75th percentile = 0.9%).^{33,54-71} (Note: This includes duplicate series from several large observational registries.) This finding has been reported with all three of the commonly used isotopes including thallium 201, technetium 99m sestamibi, and Tc-99m tetrofosmin. Most recently, a combined series evaluating near-term prognosis in all three agents was reported in 10,408 patients noting equivalent cardiac death rates (ie, 0.6% per year over a 3-year period of follow-up).³³ Furthermore, the finding of an exceedingly low event rate over a 7-year period of follow-up has recently been reported.⁵⁴ These findings are important in symptomatic cohorts, such as is noted in the 19 published series, and reflect the value of evaluating the physiology of the disease state in addition to anatomic extent and severity of stenoses. Thus, although obstructive coronary disease may be present, normal perfusion findings reveal that the disease is not flow-limiting and that, on the basis of this evidence, it is not prognostically significant. It is also important to note that a rate of 0.6% per year is similar to an intermediate-risk, asymptomatic cohort, as has been noted in prior reports from the National Cholesterol Education Program Adult Treatment Panel III and Framingham risk score estimates.^{35,36}

There are important caveats to this assessment including the notation that the event rate in patients with a normal perfusion SPECT study is dependent on the underlying risk in the population. That is, our synthesis of evidence noted an annualized event rate of 0.6% and reflects the average expected yearly occurrence of cardiac death and nonfatal myocardial infarction for intermediate-risk patients with normal perfusion findings. However, higher event rates would be expected for patients with established disease or those with higher risk equivalents (including diabetic patients, the elderly, and those with existing peripheral arterial disease or undergoing pharmacologic stress imaging). The risk in these latter cohorts is higher as a result of a greater disease and comorbidity burden. On the basis of published evidence, we can expect that normal perfusion would be defined with adverse event rates of 1% to 2% per year in patients with existing cardiovascular disease and including (symptomatic) diabetic patient populations. As noted in asymptomatic population reports, patients with existing disease have an expected rate of cardiac death or nonfatal myocardial infarction of 2% per year. In two recent

Table 1. Prognostic value of normal or low-risk myocardial perfusion SPECT in estimating cardiac death and nonfatal myocardial infarction rates per year of follow-up

Year	Author	N	Agent	Average follow-up (y)	Annualized event rate (%)
2003	Elhendy ⁵⁴	218	MIBI	7.4	0.7
2003	Hachamovitch ⁵⁵	7,376	Tl/MIBI	1.8	0.6
2003	Shaw ³³	10,408	Tl/MIBI/Tetro	3.0	0.6
2002	Gibson ⁵⁶	729	MIBI	1.8	0.3
2001	Galassi ⁵⁷	459	Tetro	3.1	0.9
2000	Groutars ⁵⁸	236	Tl-201/Tetro	2.1	0.4
1999	Soman ⁵⁹	473	MIBI	2.5	0.2
1999	Gibbons ⁶⁰	4,649	Tl-201/MIBI	7.0	0.4
1999	Vanzetto ⁶¹	1,137	Tl-201	6.0	0.6
1998	Alkeylani ⁶²	1,086	MIBI	2.3	0.6
1998	Hachamovitch ⁶³	5,183	Tl-201/MIBI	1.8	0.8
1998	Olmos ⁶⁴	225	Tl-201	3.7	0.9
1997	Boyne ⁶⁵	229	MIBI	1.6	0.8
1997	Snader ⁶⁶	3,400	Tl-201	2.0	1
1996	Geleijnse ⁶⁷	392	MIBI	1.8	0.8
1995	Heller ⁶⁸	512	MIBI	12.8	1.3
1994	Kamal ⁶⁹	177	Tl-201	1.8	0
1994	Machecourt ⁷⁰	1,926	Tl-201	2.8	0.5
1994	Stratmann ⁷¹	534	MIBI	1.1	1.6
SPECT experience: 10 years [median (25th– 75th percentile)]		39,173*		2.3 (1.8-3.0)	0.6 (0.5-0.9)

MIBI, Tc-99m sestamibi; Tetro, Tc-99m tetrofosmin.
*Total n includes duplicate series.

reports in patients with normal perfusion findings, the annual rate of cardiac death was approximately 0.9% for patients with a prior history of coronary disease as compared with 0.2% for those without a prior diagnosis.^{33,55} Thus an elevated risk would warrant a closer posttest evaluation with recommended serial testing as soon as at 1 year of follow-up.⁵⁵ Thus these results are consistent with the “low end” of expected risk in this subset with an elevated risk. It is important to realize that those with chronic coronary disease (or its equivalents) have substantively higher event rates, in the setting of normal perfusion findings, but there remains a clear separation between low-risk and moderately to severely abnormal findings. Figure 1 illustrates the expected event rates with low- to high-risk SPECT findings in varying patient populations. As is noted in this figure, there is a clear separation in risk between low- to high-risk subsets of the population; however, the expected risk in the population increases proportionally.

RISK OF EVENTS IN PATIENTS WITH ABNORMAL MYOCARDIAL PERFUSION SPECT RESULTS

In the setting of moderate-severely abnormal myocardial perfusion SPECT, rates of “hard” cardiac events, notably cardiac death and nonfatal myocardial infarction, increase logarithmically over and above patients with low-risk findings. As previously noted, the relative increase (ie, x-fold) in risk is commonly calculated by use of a relative risk ratio. On average, relative risk ratios are increased 5- to 7-fold, with the results being highly dependent on the available sample size.⁸ In larger populations (ie, >1,000 patients), relative risk ratios are elevated 3- to 5-fold.⁸ The absolute risk of events as reported in 39 reports (N = 69,655 [including duplicate series]) is shown in Table 2.^{50,53,57,61-71,72-96} Although the definition of high risk varies with the published series, it typically includes patients with moderately to severely abnormal scans, multivessel perfusion abnor-




Figure 1. Scatter plot of the relationship of population event rates to annual rates of cardiac death or nonfatal myocardial infarction in patients with low-risk or normal perfusion and high-risk SPECT imaging findings (eg, summed stress score >8 , moderately to severely abnormal or multivessel perfusion patterns). These results reveal that event rates are decidedly lower in populations with suspected coronary disease (CAD) (defined as annual event rate $<2\%$) as compared with patients with chronic coronary disease (defined as annual event rate $\geq 2\%$). Of the latter patients, those with high-risk, severe and extensive disease exhibit the highest overall event rates (defined as annual event rates $\geq 5\%$).

malities, or a summed stress score greater than 8.^{8,50,53,57,61-71,72-96}

Although we will not specifically discuss the types of defects, the literature supports the concept that the extent of fixed defects provides a better estimation of cardiac death and that reversible defects often predict acute ischemic events. Thus the combination of estimating cardiac death or nonfatal myocardial infarction would balance prognostication by using both of these defect markers. However, in populations with known coronary disease, the identification of extensive fixed perfusion abnormalities would be highly predictive of worsening cardiac survival. This latter point may be lost in a discussion using the summed stress score in which both inducible and fixed defects are noted. This same high-risk cohort with extensive fixed defects would also be commonly identified with rest and stress gated left ventricular function, where a large proportion of this group would have an impaired ejection fraction (to be discussed later in this review).

The median annual rate of major adverse cardiac events in the setting of high-risk perfusion abnormalities is 5.9% (25th percentile = 4.6%, 75th percentile = 8.5%).^{50,53,57,61-71,72-96} The recent stable angina guidelines note high risk, in patients with chronic coronary disease, as annualized event rates in the range of 3% to 5% or higher.⁹⁷ Thus evidence of high-risk, moderately to severely abnormal myocardial perfusion findings has the associated risk to a patient with chronic coronary

disease (including severely obstructive lesions and/or multivessel disease). Therefore posttest management in this high-risk cohort should be aggressive and include consideration of coronary angiography as well as optimized anti-ischemic therapy and risk factor modification. An example of this nuclear-based management strategy is currently being evaluated in the Department of Veteran's Affairs and Medical Research Council of Canada's COURAGE trial.²⁸

RISK OF EVENTS BY POSTSTRESS MEASURES OF LEFT VENTRICULAR FUNCTION

Although nuclear cardiology has been capable of obtaining measures of left ventricular function by first-pass and gated techniques for a number of decades, today rest and poststress estimations of systolic function are frequently performed as gated SPECT imaging. Estimates of left ventricular dysfunction are perhaps one of our greatest known prognosticators in cardiovascular medicine. In this era of gated SPECT imaging, a number of recent reports have provided an estimate of the current predictive value of this measure (Figure 2).⁹⁸⁻¹⁰⁴ This evidence is consistent with reports using angiographic and echocardiographic estimates noting an inversely proportional relationship between left ventricular ejection fraction measurements and event-free survival. That is, lower ejection fraction values are associated with higher event rates. A synthesis of this evidence using

Table 2. Prognostic value of normal (low-risk) and moderately to severely abnormal (high-risk) myocardial perfusion SPECT in estimating annual rates of cardiac death and nonfatal myocardial infarction

Year	Author	n	Agent	Average follow-up (y)	Annual event rate	High risk	Low risk
2003	Elhendy ⁷²	327	MIBI	7.0	3.8	6.9	—
2003	Patel ⁷³	174	MIBI	3.5	2.0	4.3	0.9
2003	Zellweger ⁷⁴	356	TI-201/MIBI	4.0	4.7	17.3	4.3
2003	Berman ⁷⁵	6,173	TI-201/MIBI	2.3	1.0	4.6	0.6
	Nondiabetic						
	Diabetic					7.4	2.2
2002	Hachamovitch ⁷⁶	10,627	TI-201/MIBI	1.9	0.7	6.7	0.7
2003	Schinkel ⁷⁷	648	Tetro	4.0	4.3	14.9	1.0
2003	Elhendy ⁷⁸	224	MIBI	7.0	3.5	7.3	—
2003	Acampa ⁷⁹	206	MIBI	3.1	3.8	5.8	1.0
2002	Schinkel ⁸⁰	528	MIBI	8.0	1.6	3.4	1.2
2002	De Lorenzo ⁸¹	108	MIBI	3.0	6.3	10.3	1.0
2002	Bravo ⁸²	150	TI-201	4.3	20.0	14.7	3.0
2002	Schinkel ⁸³	721	Tetro	3.1	2.8	5.1	1.0
2002	Feola ⁸⁴	82	TI-201	2.3	3.0	11.9	0.0
2003	Hachamovitch ⁸⁵	3,058	TI-201/MIBI	18.0	1.4	3.9	0.4
2002	Groutars ⁸⁶	597	Tetro	2.0	3.9	5.3	0.7
2001	Calnon ⁸⁷	308	MIBI	1.8	5.8	10.0	2.3
2001	Galassi ⁵⁷	459	Tetro	3.2	2.5	10.7	0.9
2001	Cottin ⁸⁸	152	TI-201	3.3	3.2	8.4	0.9
2001	Diaz ⁵⁰	7,163	TI-201	6.7	1.8	3.6	1.3
2000	Shaw ⁵³	8,411	MIBI/TI-201	2.5	1.2	5.0	0.5
2000	Kaminek ⁸⁹	70	TI-201/MIBI	2.1	1.4	10.7	1.2
2000	Amanullah ⁹⁰	633	TI-201/MIBI	1.8	6.0	5.4	0.8
1999	Vanzetto ⁶¹	1,137	Thallium	6.0	1.5	2.0	0.6
1999	Kang ⁹¹	1,271	TI-201/MIBI	2.0	3.3	7.0	1.5
1998	Hachamovitch ⁶³	5,183	TI-201/MIBI	1.8	3.0	5.9	0.8
1998	Olmos ⁶⁴	225	TI-201	3.7	1.8	2.7	0.9
1998	Alkeylani ⁶²	1,086	MIBI	2.3	3.4	5.0	0.6
1997	Snader ⁶⁶	3,400	Thallium	2.0	1.6	3.8	1.0
1997	Boyne ⁶⁵	229	MIBI	1.6	2.2	5.1	0.8
1997	Hachamovitch ⁹²	1,159	TI-201/MIBI	2.3	4.5	4.6	0.7
1996	Geleijnse ⁶⁷	392	MIBI	1.8	6.0	8.7	0.8
1996	Hachamovitch ⁹³	4,136	TI-201/MIBI	1.7	1.4	6.8	0.6
1996	Hachamovitch ⁹⁴	2,200	TI-201/MIBI	1.6	1.1	6.3	0.2
1995	Hachamovitch ⁹⁵	3,211	TI-201/MIBI	1.6	1.9	5.2	0.6
1995	Berman ⁹⁶	1,702	TI-201/MIBI	1.7	1.8	4.4	0.2
1995	Heller ⁶⁸	512	MIBI	12.8	4.6	6.9	1.3
1994	Machecourt ⁷⁰	1,926	Thallium	2.8	2.0	2.9	0.5
1994	Kamal ⁶⁹	177	Thallium	1.8	4.3	5.2	0.0
1994	Stratmann ⁷¹	534	MIBI	1.1	10.1	14.3	1.6
SPECT experience: 10 years [median (25th– 75th percentile)]		69,655*		2.3 (1.8-3.9)	3.0 (1.7-4.3)	5.9 (4.6-8.5)	0.85 (0.6-1.2)

MIBI, Tc-99m sestamibi; Tetro, Tc-99m tetrofosmin.
*Total n includes duplicate series.




Figure 2. Cumulative evidence on prognosis associated with poststress gated SPECT measurements of left ventricular function. The line of best fit (*solid line*) is based on a power regression function (95% CI, *dotted lines*) optimizing explanatory variation.

gated SPECT imaging noted cardiac event rates ranging, on average, from 2.4% to 17.3% for measures of 60% to 20% or less.⁹⁸⁻¹⁰⁴ On the basis of these six reports and a prior meta-analysis, one can estimate the expected rate of events from the ejection fraction value by using the following equation: $y = 1.48x^{-2}$, in which y is the cardiac event rate and x is the left ventricular ejection fraction. These data reveal a strong and log-linear relationship between ejection fraction measurements and rates of major adverse cardiac events.

Although we did not specifically discuss the data on left ventricular volumes, recent evidence suggests that end-diastolic and end-systolic volume data would further help to refine prognostication by measures of left ventricular function. In fact, in one recent report, end-systolic volume provided independent predictive value over and above left ventricular ejection fraction.¹⁰³ In particular, an end-systolic volume greater than 70 mL was associated with worsening 2-year survival.¹⁰³ Left ventricular remodeling (ie, end-diastolic volume measures) has also been an important guide to therapeutic decision making in patients with systolic dysfunction and evidence of myocardial viability. Other measures of ventricular impairment including transient ischemic dilation are also of prognostic significance.¹⁰⁵ In this case high risk is defined by transient ischemic dilation greater than 1.21.¹⁰⁵ This latter study was performed in patients with normal perfusion findings and suggests that it is important to consider other findings including ventricular size, function, and evidence of dilation after stress.

INTEGRATIVE MANAGEMENT APPROACHES

One of the benefits of the wealth of evidence on prognosis with SPECT imaging is that the data can be

easily integrated into risk-based patient management algorithms. There are several examples of risk-based algorithms that have been developed in certain patient cohorts. For example, a recent taskforce of the American Society of Nuclear Cardiology has published an evidence-based guideline for at-risk women focusing on selecting candidates who receive the greatest incremental value from referral to SPECT imaging.¹⁰⁶ Another example of a risk-based patient management algorithm is currently being tested in the COURAGE trial.²⁸ This trial will enroll approximately 3,000 patients with coronary disease who are then randomized to optimal anti-ischemic and risk factor modification therapies as compared with percutaneous coronary interventions plus medical management. After enrollment, it is recommended that patients who have recurrent or worsening (but not unstable) chest pain undergo gated SPECT imaging with initial risk stratification based on left ventricular ejection fraction measures followed by the extent and severity of inducible ischemia. On the basis of the expected risk in each patient subset, high-risk subsets undergo re-angiography for the assessment of progressive coronary disease.

HIGH-RISK FINDINGS AND HIGH-RISK PATIENT SUBSETS

A review of evidence suggests that high-risk findings on SPECT imaging include patients whose expected rate of major adverse cardiac events is 3% to 5% or more and patients with moderately to severely abnormal perfusion abnormalities, multivessel perfusion abnormalities, or a summed stress score greater than 8. Patients with a high-risk poststress left ventricular ejection fraction lower than 45% are at an elevated risk of major adverse cardiac events. Other high-risk markers include




Figure 3. Expected risk of major adverse cardiac events in patients with suspected to chronic coronary disease (CAD) based on SPECT findings of low-risk (ie, normal perfusion) or high-risk myocardial perfusion results (eg, summed stress score >8, moderately to severely abnormal or multivessel perfusion patterns). *Chronic CAD*, Known coronary disease and risk equivalents (ie, pharmacologic stress, peripheral arterial disease, diabetic patients).

transient ischemic dilation, larger ventricular volumes, and increased lung uptake by Tl-201 imaging.⁶

A review of evidence suggests that optimal use of risk data is dependent on understanding the underlying risk in the population. Figure 3 notes the varying cardiac event rates in patients with suspected to chronic coronary disease. As expected, lower event rates are noted for patients without a prior coronary disease diagnosis. We also have extended our evaluation of the chronic coronary disease patient series to include those patient cohorts whose cardiac event risk is equivalent to a diseased population. This risk-equivalent population should also include patients with diabetes, those with evidence of peripheral arterial disease, and those referred to pharmacologic stress imaging.

OPTIMAL REFERRAL CANDIDATES BASED ON ADDED RISK EFFECTIVENESS

Although this review has focused on risk assessment in suspected or known coronary disease, there are specific subsets of patients for whom risk assessment is particularly valuable, with abundant evidence, including diabetics,^{75,81,91,107,108} women,¹⁰⁹⁻¹¹⁰ and patients referred to pharmacologic stress imaging.^{53,55,63,67-69,71-72,75,78,80,82-83,85,92} Figure 4 depicts a synthesis of evidence on the prognostic value of myocardial perfusion SPECT by sex and diabetes mellitus. These results reveal that expected event rates are higher in women and diabetic patients.^{75,81,91,107-110} However, diabetic women are the highest-risk cohort, with expected event rates approximately 10% to 40% higher than those of their male counterparts (Figure 4).

Synthesizing from published reports, the expected annual risk of cardiac death or nonfatal myocardial infarction is decidedly higher in patients referred to pharmacologic stress imaging including intravenous adenosine, dipyridamole, or dobutamine imaging (Figure 5), as compared with higher-functioning patients capable of performing exercise testing. Low-risk and high-risk patients undergoing pharmacologic stress imaging have an annual cardiac event risk of 1.2% and 8.3%, respectively, as compared with 0.7% and 5.6%, respectively, for exercising patients.

FUTURE APPLICATIONS OF OUTCOMES ASSESSMENT IN NUCLEAR CARDIOLOGY

Although the paradigm of estimating risk has added tremendous value to the use of nuclear imaging in guiding patient management decisions, its concept is largely based on the principle of defining the natural history of myocardial perfusion and ventricular function abnormalities. That is, we have defined SPECT risk markers as being associated with major adverse event rates of 4.8% to 8.5% (25th to 75th percentile) per year.^{50,53,57,61-96} However, in our current era of aggressive management, the hope for patients is that optimal intervention, including anti-ischemic therapy, risk factor modification, and revascularization (if necessary), would improve the expected adverse outcome of at-risk patients. By use of our existing Cox proportional hazards models, patients who undergo coronary revascularization are censored during the analytical process. Therefore the true benefit of nuclear imaging is that risk is identified and the ensuing natural history is changed by important risk-reducing therapies.

Future applications in SPECT imaging are unfolding, in which SPECT risk markers serve as surrogate or intermediate outcomes. With this reasoning, SPECT is performed serially to examine changes in perfusion and function after the initiation of a given treatment strategy. The key to using SPECT risk markers as surrogate outcomes is that a given threshold of change in perfusion or function should signify a worsening of or improvement in patient outcome. This is optimally what clinicians and patients expect from any given test referral; they hope to garner information on disease presence and severity so that changes in management can return patients to full functioning and a healthy quality of life.

Recently, an increasing number of reports have used serial SPECT imaging to define the effectiveness of therapies to diminish inducible ischemia concomitant with control of anginal symptoms.⁹⁻³¹ The pathophysiologic basis for the use of SPECT is that the onset of an acute coronary syndrome is initiated by impaired vasomotion along with plaque rupture of a subcritical stenosis. SPECT imaging plays a critical role in identifying




Figure 4. Annual risk of cardiac death or nonfatal myocardial infarction (*MI*) in important patient subsets referred to gated SPECT imaging including diabetic and nondiabetic women and men. This series includes prognostic data on symptomatic women and men as well as asymptomatic and symptomatic diabetic patients.




Figure 5. Annual risk of cardiac death or nonfatal myocardial infarction (*MI*) in patients referred to exercise and pharmacologic stress myocardial perfusion SPECT imaging.

risk by defining the extent and severity of reduced blood flow with an established relationship in estimating acute ischemic events. Not only will anti-ischemic therapies affect endothelial function, but statins also exhibit a beneficial effect and reduce ischemic events through a number of mechanisms (eg, improving endothelial function, reduced inflammation, and plaque stabilization).^{9,31}

The use of SPECT as a surrogate outcome is based on numerous randomized trials and American College of Cardiology/American Heart Association guidelines noting that ischemia-guided therapy results in optimal patient selection and greater proportional risk reduction.^{9-31,97} Although several prior reports have noted the use of SPECT imaging in assessing restenosis approximately 6 months after percutaneous coronary intervention,¹¹¹⁻¹²² more recently, optimal medical management has been applied in several controlled clinical trials.⁹⁻³¹ In general, on the second scan, a threshold of change (ie,

change in summed stress score ≥ 3 or $\geq 9\%$ change in quantitative estimates) in ischemic defect size, extent, and severity reflects a clinical worsening or improvement, depending on the direction (eg, increase in summed stress score from 6 to 10 indicates worsening) of change. Preliminary results have revealed that 50% to 89% of patients will exhibit significant improvement in inducible ischemia after the initiation of aggressive anti-ischemic therapies and risk factor modification.^{27,30,31} In a recent small series by Schwartz et al,³¹ 6 months of statin therapy in patients with chronic coronary disease was associated with 61% of patients exhibiting improvements in inducible ischemia from baseline. Although there have been a number of small series using SPECT as a surrogate outcome, there are currently a number of ongoing clinical trials that are using serial monitoring with SPECT imaging including the following: Bypass Angioplasty Investigation 2-D (in diabetic




Figure 6. Risk-based patient management approach for patients with suspected or known coronary artery disease (CAD). An additional high-risk cohort is included and defined as patients whose cardiac event risk is equivalent to a population with existing disease. This cardiac risk-equivalent population is defined as those referred to pharmacologic stress imaging, patients with peripheral arterial disease, or diabetic patients (ie, annual risk of death or myocardial infarction $\geq 2.0\%$). EF, Ejection fraction.

*Other Markers include Transient Ischemic Dilation, Increased Lung Uptake, or Decreased Left Ventricular Volumes.

patients) (BARI 2-D), COURAGE, and Adenosine Sestamibi spect Post-Infarction Evaluation (INSPIRE).^{28,30} INSPIRE is a randomized, prospective, multicenter trial designed to evaluate the role of optimal anti-ischemic and risk factor-reducing therapy with the use of adenosine Tc-99m sestamibi SPECT in low-risk, post-myocardial infarction patients.³⁰ The COURAGE trial is a randomized trial comparing optimal medical therapy (anti-ischemic and risk factor modification) as compared with percutaneous coronary interventions (including medical management) and enrolling more than 3,000 patients with chronic coronary disease.²⁸ An example of serial monitoring with SPECT has recently been published by O'Rourke et al.¹¹ Preliminary results from these larger trials reveal that aggressive management can ameliorate patient symptoms as well as SPECT-induced ischemia in a large proportion of patients (ie, $>50\%$ and $<90\%$).^{27,30,31}

CONCLUSION

This review provides a synopsis of available evidence on the prognostic value of gated myocardial perfusion SPECT. The magnitude of this evidence provides substantial documentation as to the maturity of this

modality. As reported in 39 peer-reviewed articles, there is a clear separation in risk of major adverse cardiac events between patients with low- and high-risk perfusion imaging results over the ensuing 2 to 4 years of follow-up. From a total of 69,655 patients (including duplicates), the median annual rate of cardiac death or nonfatal myocardial infarction was 5.9% for those with high-risk SPECT results. For patients with normal perfusion results ($n = 39,173$), the median rate of cardiac death or nonfatal myocardial infarction was 0.6% per year. On the basis of this evidence, the intensity of posttest management may be guided by expected rates of cardiac events based on the results of SPECT imaging; intensive management (considering coronary angiography in conjunction with aggressive risk factor modification and anti-ischemic therapy) should be applied to those high-risk patients (Figure 6). Although this evidence on prognostication is substantial, future applications in the area of outcomes evaluation will focus on altering these expected adverse sequelae in high-risk patients (ie, natural history) by applying serial SPECT monitoring for observation of therapeutic effectiveness.

To date, the wealth of prognostic evidence with SPECT imaging has been developed and guided by many pioneers (and their collaborators) in the field, without

whose contribution this review would not be possible. There clearly is no other noninvasive modality whose body of evidence has unfolded over the past few decades and whose depth of evidence in the area of prognostication may be used to guide management of many important patient subsets (only a few of the major indications have been highlighted herein). Thus, as we look to the future, our hope is that gated SPECT imaging research will continue to reveal evidence and guide future applications by using this well-established template of defining an imaging modality's value by the depth and accumulation of high-quality prognostic evidence.

Acknowledgment

The authors have indicated they have no financial conflicts of interest.

References

1. Available at American Heart Association Web site: <http://www.americanheart.org/statistics/economic.html>. Accessed December 10, 2003.
2. Levin DC, Parker L, Intenzo CM, Sunshine JH. Recent rapid increase in utilization of radionuclide myocardial perfusion imaging and related procedures: 1996-1998 practice patterns. *Radiology* 2002;222:144-8.
3. Mark DB, Shaw LJ, Lauer MS, O'Malley P, Heidenreich P. 34th Bethesda Conference: Task force #5—is atherosclerotic imaging cost effective? *J Am Coll Cardiol* 2003;41:1906-17.
4. Available at American College of Cardiology Web site: http://www.acc.org/advocacy/advoc_issues/impactchart.htm. Accessed December 10, 2003.
5. Underwood SR, Anagnostopoulos C, Cerqueira M, et al. Myocardial perfusion scintigraphy: the evidenceA consensus conference organised by the British Cardiac Society, the British Nuclear Cardiology Society and the British Nuclear Medicine Society, endorsed by the Royal College of Physicians of London and the Royal College of Radiologists. *Eur J Nucl Med Mol Imaging* 2003;31:261-91.
6. Berman DS, Shaw LJ, Germano G. Nuclear cardiology. In: Fuster V, Alexander RW, O'Rourke RA, editors. *Hurst's the heart*. 10th ed. New York: McGraw-Hill; 2001. p. 525-65.
7. Yusuf S, Zucker D, Peduzzi P, et al. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration [published erratum appears in *Lancet* 1994;344:1446]. *Lancet* 1994;344:563-70.
8. Califf RM, Armstrong PW, Carver JR, D'Agostino RB, Strauss WE. Stratification of patients into high, medium, and low risk subgroups for purposes of risk factor management. *J Am Coll Cardiol* 1996;27:964-1047.
9. Sdringola S, Nakagawa K, Nakagawa Y, et al. Combined intensive lifestyle and pharmacologic lipid treatment further reduce coronary events and myocardial perfusion abnormalities compared with usual-care cholesterol-lowering drugs in coronary artery disease. *J Am Coll Cardiol* 2003;41:263-72.
10. Parisi AF, Hartigan PM, Folland ED. Evaluation of exercise thallium scintigraphy versus exercise electrocardiography in predicting survival outcomes and morbid cardiac events in patients with single- and double-vessel disease. Findings from the Angioplasty Compared to Medicine (ACME) study. *J Am Coll Cardiol* 1997;30:1256-63.
11. O'Rourke RA, Chaudhuri T, Shaw L, Berman DS. Resolution of stress-induced myocardial ischemia during aggressive medical therapy as demonstrated by single photon emission computed tomography imaging. *Circulation* 2001;103:2315.
12. Mostaza JM, Gomez MV, Gallardo F, et al. Cholesterol reduction improves myocardial perfusion abnormalities in patients with coronary artery disease and average cholesterol levels. *J Am Coll Cardiol* 2000;35:76-82.
13. Mahmarian JJ, Fenimore NL, Marks GF, et al. Transdermal nitroglycerin patch therapy reduces the extent of exercise-induced myocardial ischemia: results of a double-blind, placebo-controlled trial using quantitative thallium-201 tomography. *J Am Coll Cardiol* 1994;24:25-32.
14. Yokoyama I, Ohtake T, Momomura S, et al. Reduced coronary flow reserve in hypercholesterolemic patients without overt coronary stenosis. *Circulation* 1996;94:3232-8.
15. Zeiher AM, Krause T, Schachinger V, et al. Impaired endothelium-dependent vasodilation of coronary resistance vessels is associated with exercise-induced myocardial ischemia. *Circulation* 1995;91:2345-52.
16. Aoki M, Sakai K, Koyanagi S, Takeshita A, Nakamura M. Effect of nitroglycerin on coronary collateral function during exercise evaluated by quantitative analysis of thallium-201 single photon emission computed tomography. *Am Heart J* 1991;121:1361-6.
17. Stegaru B, Loose R, Keller H, Buss J, Wetzel E. Effects of long-term treatment with 120 mg of sustained-release isosorbide dinitrate and 60 mg of sustained-release nifedipine on myocardial perfusion. *Am J Cardiol* 1988;61:74E-7E.
18. Zacca NM, Verani MS, Chahine RA, Miller RR. Effect of nifedipine on exercise-induced left ventricular dysfunction and myocardial hypoperfusion in stable angina. *Am J Cardiol* 1982; 50:689-95.
19. Sharir T, Rabinowitz B, Chouraqui P. Anti-ischemic drugs reduce size of reversible defects in dipyridamole/submaximal exercise TI-201 SPECT imaging [abstract]. *J Nucl Cardiol* 1997;4:S71.
20. Shehata AR, Mascitelli VA, Herman SD, et al. Impact of acute propranolol administration on dobutamine-induced myocardial ischemia as evaluated by myocardial perfusion imaging and echocardiography. *Am J Cardiol* 1997;80:268-72.
21. Cid E, Mahmarian JJ. Factors affecting the diagnostic accuracy of quantitative single photon tomography combined with dobutamine stress [abstract]. *J Nucl Med* 1996;37:58P.
22. Gould KL, Ornish D, Scherwitz L, et al. Changes in myocardial perfusion abnormalities by positron emission tomography after long-term, intense risk factor modification. *JAMA* 1995;274:894-901.
23. Gould KL. Reversal of coronary atherosclerosis. Clinical promise as the basis for noninvasive management of coronary artery disease. *Circulation* 1994;90:1558-71.
24. Eichstadt HW, Eskotter H, Hoffman I, Amthauer HW, Weidinger G. Improvement of myocardial perfusion by short-term fluvastatin therapy in coronary artery disease. *Am J Cardiol* 1995;76: 122A-5A.
25. Dakik HA, Kleiman NS, Farmer JA, et al. Intensive medical therapy versus coronary angioplasty for suppression of myocardial ischemia in survivors of acute myocardial infarction: a prospective, randomized pilot study. *Circulation* 1998;98:2017-23.
26. Lewin HC, Berman DS. Achieving sustained improvement in myocardial perfusion: role of isosorbide mononitrate. *Am J Cardiol* 1997;79:31-5.

27. Hayes SW, Shaw LJ, O'Rourke RA, et al. COURAGE Investigators. Relationship between clinical site and core lab assessments of perfusion and function on stress gated myocardial perfusion SPECT. *J Am Coll Cardiol* 2001;37:438A.
28. Boden WE, Weintraub WS, O'Rourke RA, et al. Review of the trials comparing medical therapy versus angioplasty and the rationale/design of the clinical outcomes utilizing percutaneous coronary revascularization and aggressive drug evaluation (COURAGE) trial. *Am Heart J*. In press 2004.
29. Mahmarian JJ, Moye LA, Verani MS, Bloom MF, Pratt CM. High reproducibility of myocardial perfusion defects in patients undergoing serial exercise thallium-201 tomography. *Am J Cardiol* 1995;75:1116-9.
30. Iskander S, Pratt CM, Filipchuk NG, et al. Medical and revascularization therapies for suppression of post-infarction myocardial ischemia. Preliminary results from the Adenosine Sestamibi Post-Infarction Evaluation (INSPIRE) trial [abstract]. *Circulation* 2001;104:II-455.
31. Schwartz RG, Pearson TA, Kalaria VG, et al. Prospective serial evaluation of myocardial perfusion and lipids during the first six months of pravastatin therapy: coronary artery disease regression single photon emission computed tomography monitoring trial. *J Am Coll Cardiol* 2003;42:600-10.
32. Abrams J, Pasternak R, Greenland P, Houston-Miller N, Smaha L. Bethesda Conference #34: identification of CHD and CHD risk: is there a detection gap? *J Am Coll Cardiol* 2003;41:1863-74.
33. Shaw LJ, Hendel R, Lauer MS, et al, for the Myoview Multicenter Registry. Prognostic value of normal exercise and adenosine Tc-99m tetrofosmin SPECT imaging: results from the multicenter registry in 4,728 patients. *J Nucl Med* 2003; 44:134-9.
34. Available at European Society of Cardiology: www.escardio.org/scinfo/Guidelines/98prevention.pdf. Accessed December 10, 2003.
35. Pasternak RC, Abrams J, Greenland P, et al. Taskforce #1—identification of coronary heart disease risk: is there a detection gap? *J Am Coll Cardiol* 2003;41:1863-74.
36. Available at NIH-NHLBI: <http://hin.nhlbi.nih.gov/atp/iii/calculator.asp?usertype=prof>. Accessed December 10, 2003.
37. Berry E, Kelly S, Hutton J, et al. A systematic literature review of spiral and electron beam computed tomography: with particular reference to clinical applications in hepatic lesions, pulmonary embolus and coronary artery disease. *Health Tech Assess* 1999; 3:1-121.
38. O'Rourke RA, Brundage BH, Froelicher VF, et al. American College of Cardiology/American Heart Association Expert Consensus document on electron-beam computed tomography for the diagnosis and prognosis of coronary artery disease. *Circulation* 2000;102:126-40.
39. Shaw RE, Anderson HV, Brindis RG, et al. Development of a risk adjustment mortality model using the American College of Cardiology—National Cardiovascular Data Registry (ACC-NCDR) experience: 1998-2000. *J Am Coll Cardiol* 2002;39:1104-12.
40. DeLong ER, Nelson CL, Wong JB, et al. Using observational data to estimate prognosis: an example using a coronary artery disease registry. *Stat Med* 2001;20:2505-32.
41. Shaw LJ, Eisenstein EL, Hachamovitch R, et al. A primer of biostatistic and economic methods for diagnostic and prognostic modeling in nuclear cardiology: part II. *J Nucl Cardiol* 1997;4:52-60.
42. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. *J Am Stat Soc* 1958;53:457-81.
43. Hosmer DW, Lemeshow S. *Applied survival analysis: regression modeling of time to event data*. New York: John Wiley and Sons, Inc; 1999.
44. Cox D. Regression models and life tables (with discussion). *J R Stat Soc B* 1972;34:187-220.
45. Concato J, Feinstein AR, Holford TR. The risk of determining risk with multivariable models. *Ann Intern Med* 1993;118:201-10.
46. Goldman L, Mudge GH Jr, Cook EF. The changing "natural history" of symptomatic coronary artery disease: basis versus bias. *Am J Cardiol* 1983;51:449-54.
47. Rubin DB. Estimating causal effects from large data sets using propensity scores. *Ann Intern Med* 1997;127:757-63.
48. Lauer MS, Blackstone EH, Young JB, Topol EJ. Cause of death in clinical research: time for a reassessment? *J Am Coll Cardiol* 1999;34:618-20.
49. Gjørup T, Kelbaek H, Stenbygaard L, et al. Effect of knowledge of serum enzyme concentrations on doctors' interpretation of electrocardiographic manifestations in suspected myocardial infarction. *Br Med J (Clin Res Ed)* 1986;292:27.
50. Diaz LA, Brunken RC, Blackstone EH, Snader CE, Lauer MS. Independent contribution of myocardial perfusion defects to exercise capacity and heart rate recovery for prediction of all-cause mortality in patients with known or suspected coronary heart disease. *J Am Coll Cardiol* 2001;37:1558-64.
51. Pearson TA. New tools for coronary risk assessment. *Circulation* 2002;105:886-92.
52. Arnell TD, de Virgilio C, Donayre C, et al. Abdominal aortic aneurysm screening in elderly males with atherosclerosis: the value of physical exam. *Am Surg* 1996;62:861-4.
53. Shaw LJ, Berman DS, Hachamovitch R, et al. Noninvasive strategies for the estimation of cardiac risk: an observational assessment of outcome in stable chest pain patients. *Am J Cardiol* 2000;86:1-7.
54. Elhendy A, Schinkel A, Bax JJ, van Domburg RT, Poldermans D. Long-term prognosis after a normal exercise stress Tc-99m sestamibi SPECT study. *J Nucl Cardiol* 2003;10:261-6.
55. Hachamovitch R, Hayes S, Friedman JD, et al. Determinants of risk and its temporal variation in patients with normal stress myocardial perfusion scans: what is the warranty period of a normal scan? *J Am Coll Cardiol* 2003;41:1329-40.
56. Gibson PB, Demus D, Noto R, Hudson W, Johnson LL. Low event rate for stress-only perfusion imaging in patients evaluated for chest pain. *J Am Coll Cardiol* 2002;39:999-1004.
57. Galassi AR, Azzarelli S, Tomaselli A, et al. Incremental prognostic value of technetium-99m-tetrofosmin exercise myocardial perfusion imaging for predicting outcomes in patients with suspected or known coronary artery disease. *Am J Cardiol* 2001;88:101-6.
58. Groutars RG, Verzijlbergen JF, Muller AJ, et al. Prognostic value and quality of life in patients with normal rest thallium-201/stress technetium 99m-tetrofosmin dual-isotope myocardial SPECT. *J Nucl Cardiol* 2000;7:333-41.
59. Soman P, Parsons A, Lahiri N, Lahiri A. The prognostic value of a normal Tc-99m sestamibi SPECT study in suspected coronary artery disease. *J Nucl Cardiol* 1999;6:252-6.
60. Gibbons RJ, Hodge DO, Berman DS, Akinboboye OO, Heo J, Hachamovitch R, Bailey KR, Iskandrian AE. Long-term outcome of patients with intermediate-risk exercise electrocardiograms who do not have myocardial perfusion defects on radionuclide imaging. *Circulation* 1999;100:2140-5.
61. Vanzetto G, Ormezzano O, Fagret D, et al. Long-term additive prognostic value of thallium-201 myocardial perfusion imaging over clinical and exercise stress test in low to intermediate risk patients: study in 1137 patients with 6-year follow-up. *Circulation* 1999;100:1521-7.
62. Alkeylani A, Miller DD, Shaw LJ, et al. Influence of race on the prediction of cardiac events with stress technetium-99m sestamibi

- tomographic imaging in patients with stable angina pectoris. *Am J Cardiol* 1998;81:293-7.
63. Hachamovitch R, Berman DS, Shaw LJ, et al. Incremental prognostic value of myocardial perfusion single photon emission computed tomography for the prediction of cardiac death: differential stratification for risk of cardiac death and myocardial infarction. *Circulation* 1998;97:535-43.
64. Olmos LI, Dakik H, Gordon R, et al. Long-term prognostic value of exercise echocardiography compared with exercise 201Tl, ECG, and clinical variables in patients evaluated for coronary artery disease. *Circulation* 1998;98:2679-86.
65. Boyne TS, Koplman BA, Parsons WJ, et al. Predicting adverse outcome with exercise SPECT technetium-99m sestamibi imaging in patients with suspected or known coronary artery disease. *Am J Cardiol* 1997;79:270-4.
66. Snader CE, Marwick TH, Pashkow FJ, et al. Importance of estimated functional capacity as a predictor of all-cause mortality among patients referred for exercise thallium single-photon emission computed tomography: report of 3,400 patients from a single center. *J Am Coll Cardiol* 1997;30:641-8.
67. Geleijnse ML, Elhendy A, van Domburg RT, et al. Prognostic value of dobutamine-atropine stress technetium-99m sestamibi perfusion scintigraphy in patients with chest pain. *J Am Coll Cardiol* 1996;28:447-54.
68. Heller GV, Herman SD, Travin MI, et al. Independent prognostic value of intravenous dipyridamole with technetium-99m sestamibi tomographic imaging in predicting cardiac events and cardiac-related hospital admissions. *J Am Coll Cardiol* 1995;26:1202-8.
69. Kamal AM, Fattah AA, Pancholy S, et al. Prognostic value of adenosine single-photon emission computed tomographic thallium imaging in medically treated patients with angiographic evidence of coronary artery disease. *J Nucl Cardiol* 1994;1:254-61.
70. Machecourt J, Longere P, Fagret D, et al. Prognostic value of thallium-201 single-photon emission computed tomographic myocardial perfusion imaging according to extent of myocardial defect. Study in 1,926 patients with follow-up at 33 months. *J Am Coll Cardiol* 1994;23:1096-106.
71. Stratmann HG, Tamesis BR, Younis LT, Wittry MD, Miller DD. Prognostic value of dipyridamole technetium-99m sestamibi myocardial tomography in patients with stable chest pain who are unable to exercise. *Am J Cardiol* 1994;73:647-52.
72. Elhendy A, Schinkel AF, van Domburg RT, Bax JJ, Poldermans D. Comparison of late outcome in patients with versus without angina pectoris having reversible perfusion abnormalities during dobutamine stress technetium-99m sestamibi single-photon emission computed tomography. *Am J Cardiol* 2003;91:264-8.
73. Patel AD, Abo-Auda WS, Davis JM, et al. Prognostic value of myocardial perfusion imaging in predicting outcome after renal transplantation. *Am J Cardiol* 2003;92:146-51.
74. Zellweger MJ, Weinbacher M, Zutter AW, et al. Long-term outcome of patients with silent versus symptomatic ischemia six months after percutaneous coronary intervention and stenting. *J Am Coll Cardiol* 2003;42:33-40.
75. Berman DS, Kang X, Hayes SW, et al. Adenosine myocardial perfusion single-photon emission computed tomography in women compared with men. Impact of diabetes mellitus on incremental prognostic value and effect on patient management. *J Am Coll Cardiol* 2003;41:1125-33.
76. Hachamovitch R, Hayes SW, Friedman JD, Cohen I, Berman DS. Comparison of the short-term survival benefit associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomography. *Circulation* 2003;107:2900-7.
77. Schinkel AF, Elhendy A, van Domburg RT, et al. Incremental value of exercise technetium-99m tetrofosmin myocardial perfusion single-photon emission computed tomography for the prediction of cardiac events. *Am J Cardiol* 2003;91:408-11.
78. Elhendy A, Schinkel AF, van Domburg RT, Bax JJ, Poldermans D. Comparison of late outcome in patients with versus without angina pectoris having reversible perfusion abnormalities during dobutamine stress technetium-99m sestamibi single-photon emission computed tomography. *Am J Cardiol* 2003;91:264-8.
79. Acampa W, Petretta M, Florimonte L, Mattered A, Cuocolo A. Prognostic value of exercise cardiac tomography performed late after percutaneous coronary intervention in symptomatic and symptom-free patients. *Am J Cardiol* 2003;91:259-63.
80. Schinkel AF, Elhendy A, Van Domburg RT, et al. Long-term prognostic value of dobutamine stress 99mTc-sestamibi SPECT: single-center experience with 8-year follow-up. *Radiology* 2002; 225:701-6.
81. De Lorenzo A, Lima RS, Siqueira-Filho AG, Pantoja MR. Prevalence and prognostic value of perfusion defects detected by stress technetium-99m sestamibi myocardial perfusion single-photon emission computed tomography in asymptomatic patients with diabetes mellitus and no known coronary artery disease. *Am J Cardiol* 2002;90:827-32.
82. Bravo N, Gimenez M, Mejia S, Garcia-Velloso MJ, Coma-Canella I. Prognostic value of myocardial perfusion imaging with adenosine triphosphate. *J Nucl Cardiol* 2002;9:395-401.
83. Schinkel AF, Elhendy A, van Domburg RT, et al. Prognostic value of dobutamine-atropine stress (99m)Tc-tetrofosmin myocardial perfusion SPECT in patients with known or suspected coronary artery disease. *J Nucl Med* 2002;43:767-72.
84. Feola M, Biggi A, Ribichini F, et al. Predicting cardiac events with Tl201 dipyridamole myocardial scintigraphy in renal transplant recipients. *J Nephrol* 2002;15:48-53.
85. Hachamovitch R, Berman DS, Kiat H, et al. Value of stress myocardial perfusion single photon emission computed tomography in patients with normal resting electrocardiograms: an evaluation of incremental prognostic value and cost-effectiveness. *Circulation* 2002;105:823-9.
86. Groutars RG, Verzijlbergen JF, Zwinderman AH, et al. Incremental prognostic value of myocardial SPET with dual-isotope rest (201)Tl/stress (99m)Tc-tetrofosmin. *Eur J Nucl Med Mol Imaging* 2002;29:46-52.
87. Calnon DA, McGrath PD, Doss AL, et al. Prognostic value of dobutamine stress technetium-99m-sestamibi single-photon emission computed tomography myocardial perfusion imaging: stratification of a high-risk population. *J Am Coll Cardiol* 2001;38:1511-7.
88. Cottin Y, Rezaizadeh K, Touzery C, et al. Long-term prognostic value of 201Tl single-photon emission computed tomographic myocardial perfusion imaging after coronary stenting. *Am Heart J* 2001;141:999-1006.
89. Kaminek M, Myslivecek M, Myslivecek M, et al. Prognostic value of myocardial perfusion tomographic imaging in patients after percutaneous transluminal coronary angioplasty. *Clin Nucl Med* 2000;25:775-8.
90. Amanullah AM, Berman DS, Kang X, et al. Enhanced prognostic stratification of patients with left ventricular hypertrophy with the use of single-photon emission computed tomography. *Am Heart J* 2000;140:456-62.
91. Kang X, Berman DS, Lewin HC, et al. Incremental prognostic value of myocardial perfusion single photon emission computed tomography in patients with diabetes mellitus. *Am Heart J* 1999;138:1025-32.
92. Hachamovitch R, Berman DS, Kiat H, Cohen I, Lewin H, Amanullah A, Kang X, Friedman J, Diamond GA. Incremental

- prognostic value of adenosine stress myocardial perfusion single photon emission computed tomography and impact on subsequent management in patients with or suspected of having myocardial ischemia. *Am J Cardiol* 1997;80:426-33.
93. Hachamovitch R, Berman DS, Kiat H, et al. Exercise myocardial perfusion SPECT in patients without known coronary artery disease: incremental prognostic value and use in risk stratification. *Circulation* 1996;93:905-14.
94. Hachamovitch R, Berman DS, Kiat H, et al. Effective risk stratification using exercise myocardial perfusion SPECT in women: gender-related differences in prognostic nuclear testing. *J Am Coll Cardiol* 1996;28:34-44.
95. Hachamovitch R, Berman DS, Kiat H, et al. Gender-related differences in clinical management after exercise nuclear testing. *J Am Coll Cardiol* 1995;26:1457-64.
96. Berman DS, Hachamovitch R, Kiat H, et al. Incremental value of prognostic testing in patients with known or suspected ischemic heart disease: a basis for optimal utilization of exercise technetium-99m sestamibi myocardial perfusion single-photon emission computed tomography. *J Am Coll Cardiol* 1995;26:639-47.
97. Gibbons RJ, Abrams J, Chatterjee K, et al; American College of Cardiology; American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). ACC/AHA 2002 guideline update for the management of patients with chronic stable angina—summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). *J Am Coll Cardiol* 2003;41:159-68.
98. Thomas GS, Miyamoto MI, Morello AP III, et al. Technetium-99m based myocardial perfusion imaging predicts clinical outcome in the community outpatient setting: the Nuclear Utility in the Community (“NUC”) Study. *J Am Coll Cardiol* 2004;43:213-23.
99. Maddahi J, Shaw LJ, Hendel RC, et al. Prediction of cardiovascular death and nonfatal myocardial infarction by stress Tc-99m tetrofosmin SPECT: results from a multicenter registry [abstract]. *J Nucl Cardiol* 2003;10:573.
100. Burns RJ, Gibbons RJ, Yi Q, et al; CORE Study Investigators. The relationships of left ventricular ejection fraction, end-systolic volume index and infarct size to six-month mortality after hospital discharge following myocardial infarction treated by thrombolysis. *J Am Coll Cardiol* 2002;39:30-6.
101. Kroll D, Farah W, McKendall GR, Reinert SE, Johnson LL. Prognostic value of stress-gated Tc-99m sestamibi SPECT after acute myocardial infarction. *Am J Cardiol* 2001;87:381-6.
102. Sharir T, Germano G, Kang X, et al. Prediction of myocardial infarction versus cardiac death by gated myocardial perfusion SPECT: risk stratification by the amount of stress-induced ischemia and the poststress ejection fraction. *J Nucl Med* 2001;42:831-7.
103. Sharir T, Germano G, Kavanagh PB, et al. Incremental prognostic value of post-stress left ventricular ejection fraction and volume by gated myocardial perfusion single photon emission computed tomography. *Circulation* 1999;100:1035-42.
104. Shaw LJ, Miller DD, Berman DS, Hachamovitch R. Clinical and economic outcomes assessment in nuclear cardiology. *Q J Nucl Med* 2000;44:138-52.
105. Abidov A, Bax JJ, Hayes SW, et al. Transient ischemic dilation ratio of the left ventricle is a significant predictor of future cardiac events in patients with otherwise normal myocardial perfusion SPECT. *J Am Coll Cardiol* 2003;42:1818-25.
106. Mieres JH, Shaw LJ, Hendel RC, et al; American Society of Nuclear Cardiology Task Force on Women and Heart Disease Writing Group on Perfusion Imaging in Women. A report of the American Society of Nuclear Cardiology Task Force on Women and Heart Disease (Writing Group on Perfusion Imaging in Women). *J Nucl Cardiol* 2003;10:95-101.
107. Giri S, Shaw LJ, Murthy DR, et al. Impact of diabetes on the risk stratification using stress single-photon emission computed tomography myocardial perfusion imaging in patients with symptoms suggestive of coronary artery disease. *Circulation* 2002;105:32-40.
108. Vanzetto G, Halimi S, Hammoud T, et al. Prediction of cardiovascular events in clinically selected high-risk NIDDM patients. Prognostic value of exercise stress test and thallium-201 single-photon emission computed tomography. *Diabetes Care* 1999;22:19-26.
109. Marwick TH, Shaw LJ, Lauer MS, et al. The noninvasive prediction of cardiac mortality in men and women with known or suspected coronary artery disease. *Am J Med* 1999;106:172-8.
110. Amanullah AM, Berman DS, Erel J, et al. Incremental prognostic value of adenosine myocardial perfusion single-photon emission computed tomography in women with suspected coronary artery disease. *Am J Cardiol* 1998;82:725-30.
111. Zellweger MJ, Berman D, Shaw L, et al. Evaluation of patients after intervention. In: Poshost G, O'Rourke R, Berman DS, et al. editors. *Imaging in cardiovascular medicine*. Philadelphia: Lippincott Williams & Wilkins; 2000.
112. Alazraki NP, Krawczynska EG, Kosinski AS, et al. Prognostic value of TI-201 SPECT for patients with multivessel coronary disease post-revascularization: results from the Emory angioplasty-surgery trial. *Am J Cardiol* 1999;84:1369-74.
113. Lauer MS, Lytle B, Pashkow F, et al. Prediction of death and myocardial infarction by screening with exercise-thallium testing after coronary-artery-bypass grafting. *Lancet* 1998;351:615-22.
114. Hecht HS, Shaw RE, Bruce TR, et al. Usefulness of tomographic thallium-201 imaging for detection of restenosis after percutaneous transluminal coronary angioplasty. *Am J Cardiol* 1990;66:1314-8.
115. Hecht HS, Shaw RE, Chin HL, et al. Silent ischemia after coronary angioplasty: evaluation of restenosis and extent of ischemia in asymptomatic patients by tomographic thallium-201 exercise imaging and comparison with symptomatic patients. *J Am Coll Cardiol* 1991;17:670-7.
116. Pfisterer M, Rickenbacher P, Kiowski W, Muller-Brand J, Burkart F. Silent ischemia after percutaneous transluminal coronary angioplasty: incidence and prognostic significance. *J Am Coll Cardiol* 1993;22:1446-54.
117. Milan E, Zoccarato O, Terzi A, et al. Technetium-99m-sestamibi SPECT to detect restenosis after successful percutaneous coronary angioplasty. *J Nucl Med* 1996;37:1300-5.
118. Miller DD, Verani MS. Current status of myocardial perfusion imaging after percutaneous transluminal coronary angioplasty. *J Am Coll Cardiol* 1994;24:260-6.
119. Breisblatt WM, Barnes JV, Weiland F, Spaccavento LJ. Incomplete revascularization in multivessel percutaneous transluminal coronary angioplasty: the role for stress thallium-201 imaging. *J Am Coll Cardiol* 1988;11:1183-90.
120. Manyari DE, Knudtson M, Kloiber R, Roth D. Sequential thallium-201 myocardial perfusion studies after successful percutaneous transluminal coronary artery angioplasty: delayed resolution of exercise-induced scintigraphic abnormalities. *Circulation* 1988;77:86-95.
121. Hirzel HO, Nuesch K, Gruentzig AR, Luetolf UM. Short- and long-term changes in myocardial perfusion after percutaneous transluminal coronary angioplasty assessed by thallium-201 exercise scintigraphy. *Circulation* 1981;63:1001-7.
122. Zellweger MJ, Lewin HC, Lai S, et al. When to stress patients after coronary artery bypass surgery? Risk stratification in patients early and late post-CABG using stress myocardial perfusion SPECT: implications of appropriate clinical strategies. *J Am Coll Cardiol* 2001;37:144-52.